OpenAI acquires Orchestra Bio to extend Rosalind into drug-development coordination
OpenAI acquired Orchestra Bio, whose platform lets biopharma teams delegate study and program monitoring to agents. OpenAI says it will combine Orchestra's team and technology with Rosalind, GPT-Rosalind and Rosalind Workbench to connect scientific findings with the studies, decisions and next steps needed to advance medicines.
Why it matters: The acquisition moves OpenAI's life-sciences strategy beyond research models and analysis tools toward coordinating drug-development programs across experiments, manufacturing, clinical timelines and partner work. That widens the potential authority and data…